ADIAL PHARMACEUTICALS, INC. (ADIL): Nasdaq/NYSE listing notice — Adial Pharma receives Nasdaq bid price deficiency notice; compliance deadline Sept 1, 2025

ADIAL PHARMACEUTICALS, INC.

Received Nasdaq notice March 5, 2025 for failing minimum bid price of $1.00 for 30 consecutive business days (Jan 17 - Mar 4, 2025).
No immediate effect on listing or trading; common stock continues on Nasdaq Capital Market under symbol ADIL.
Company has until September 1, 2025 (180 days) to regain compliance by achieving $1.00 closing bid for 10 consecutive days.
If noncompliant by Sept 1, Company may be eligible for additional 180-day period if meets other listing standards.
Company considering available options, including a reverse stock split, to cure the bid price deficiency.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ADIAL PHARMACEUTICALS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

March 5, 2025, Adial Pharmaceuticals, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days (January 17, 2025 through March 4, 2025), the Company’s common stock did not maintain a minimum closing bid price of $1.00 (“Minimum Bid Price Requirement”) per share as required by Nasdaq Listing Rule 5550(a)(2). The notice has no immediate effect on the listing or trading of the Company’s common stock and the common stock will continue to trade on The Na

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

ADIAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-25-021738

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.